• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Tackling influenza with broadly neutralizing antibodies

tetano

Editor, Senior Moderator
Curr Opin Virol. 2017 May 18;24:60-69. doi: 10.1016/j.coviro.2017.03.002. [Epub ahead of print]
[h=1]Tackling influenza with broadly neutralizing antibodies.[/h] Corti D[SUP]1[/SUP], Cameroni E[SUP]2[/SUP], Guarino B[SUP]2[/SUP], Kallewaard NL[SUP]3[/SUP], Zhu Q[SUP]3[/SUP], Lanzavecchia A[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last decade, new methods have allowed the efficient interrogation of the human antibody repertoire from influenza immune individuals and the isolation of several monoclonal antibodies capable of dealing with the high variability of influenza viruses. Here, we will provide a comprehensive overview of the specificity, antiviral and immunological mechanisms of action and development into the clinic of broadly reactive monoclonal antibodies against influenza A and B viruses.
Copyright ? 2017 Elsevier B.V. All rights reserved.


PMID: 28527859 DOI: 10.1016/j.coviro.2017.03.002
 
Back
Top Bottom